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(1.58 vs. 0.36, p0.01), physician (10.17 vs.8.96, p0.01) and ED visits (1.12 vs. 0.67,
p0.01) than NoRxOP patients in the follow-up period. RxOP users had twice the
total healthcare costs ($49,766 vs. $19,875, p0.01) than NoRxOp patients.
CONCLUSIONS: A large percentage of patients are prescribed opioids for the first
time during ED/inpatient visits and incur a significantly higher resource use and
economic burden than those who are not.
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OBJECTIVES: Schizophrenia and bipolar disorder (BD) are psychiatric disorders
that are associated with a substantial clinical and economic burden. Hospitaliza-
tion and in-patient care commonly account for a large proportion of medical costs
in these illnesses. A secondary objective of the Italian Burden of Illness on Schizo-
phrenia and BD (IBIS) study is to assess any differences in terms of cost of illness for
patients with schizophrenia and BD switching from QTP-IR to QTP-XR.METHODS:
Multicenter, retrospective, observational, real world cohort study (NCT01392482).
The data shown are interim results collected from administrative databases in 6 of
20 Italian Local Health Units included in the study. Data were collected between 1
January 2009 and 31 December 2010. Patients that switched fromQTP-IR to QTP-XR
were included for analysis. Data were collected 6 months before (IR period) and 6
months after (XR period) the switch. RESULTS: In total, 213 patients switched
medication from QTP-IR to QTP-XR (86 with schizophrenia, 127 with BD). For pa-
tients with schizophrenia, disease-related costs per patient totaled €4123 during
the IR period and €3832 during the XR period, indicating a decrease of 7%. Although
hospitalization costs per patient remained similar after the switch (IR period:
€1111, 26.9% of total costs; XR period: €998, 26.0% of total costs), care/nursing home
costs decreased in the XR period (IR period: €1906, 46.2% of total costs; XR period:
€1330, 34.7% of total costs). For patients with BD, disease-related costs per patient
decreased by 23%, from €3877 during the IR period to €2,973 during the XR period.
Hospitalization costs per patient fell substantially after the switch (IR period: €2659,
68.6% of total costs; XR period: €1,171, 39.4% of total costs). CONCLUSIONS: These
interim results suggest that switching from QTP-IR to QTP-XR decreases direct
health care costs and in-patient resource use.
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OBJECTIVES: To assess the cost-consequences of cardiometabolic effects of lurasi-
done versus other atypical antipsychotics in adults with schizophrenia and com-
pare the results based on published cardiovascular and diabetes risk equations
from the Framingham Heart Study (FHS), the Atherosclerosis Risk in Communities
study (ARIC), and the San Antonio Heart Study (SAHS).METHODS: A discrete event
simulation model was developed to simulate the economic outcomes based on
cardiometabolic parameter changes after 1-year treatment. With a 3-year time
horizon, the model predicted the number of: 1) incident diabetes cases using each
of the risk equations, and 2) cardiovascular events (e.g., coronary heart disease
(CHD), stroke) (CVD) based on updated cardiometabolic values at 1 year, and esti-
mated the costs associated with each event. Data were drawn from comparative
clinical trials of lurasidone for lurasidone, risperidone, and quetiapine, and from
the literature for olanzapine. Cost data in 2011 values were obtained from public
data sources and discounted at 3.5% annually. RESULTS: Compared with olanzap-
ine, risperidone, and quetiapine, lurasidone: 1) avoided 119, 15, and 7 diabetes
cases and saved $1708, $192, and $95 per patient, excluding the costs of antipsy-
chotics and other events, respectively, when using FHS equation; 2) avoided 58, 8,
and 0 diabetes cases and saved $1,036, $114, and $22 when using SAHS equation;
and 3) avoided 52, 7, and 7 diabetes cases and saved $900, $76, and $88 when using
ARIC equation. Incidence of other CVD eventswas low across all drugs in themodel
due to the short time-horizon. Lurasidone saved$9600 per patient in all compar-
isons when costs of other CVD events and antipsychotics were included.
CONCLUSIONS: In this analysis, lurasidone was a cost-saving option compared to
other antipsychotics. Although the magnitude of cost savings with lurasidone dif-
fered based on the risk equation used, cost savings with lurasidone were consis-
tently observed.
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OBJECTIVES: The aim of this study is to assess the health system and patient costs
associated with antidepressant (AD) use considering the presence and persistence
of depression and anxiety. METHODS: The data was retained from a population-
based health survey on 2004 community dwelling older adults aged  65 years
participating in the ESA (Étude sur la Santé des Aînés) study. Depression and anx-
iety were assessed using DSM-IV criteria and measured at 2 time points one year
apart. Medical and non-medical costs were considered. Medication and health
service use and costs were identified from provincial administrative databases.
The excess costs associated with AD use as a function of mental health status was
analysed using generalized linear models with a gamma distribution (log link),
controlling for a number of factors.RESULTS:The prevalence of antidepressant use
reached 15.5%: SSRIs followed by TCAs were the most common. Significantly
higher health care costs (	: $2840, Wald 260.00, df1, p0.0001) were associated
with ADuse. Among antidepressant users, the results did not show any differences
in costs when accounting for dosage, the number of episodes of use and the pres-
ence of antidepressant switches. Among persistent cases of depression and anxi-
ety the use of AD was associated with lower adjusted total costs reaching CDN
$2724 and CDN $2114, respectively. The use of AD can result in cost savings reach-
ing $154.6 million and $118.4 million per 1 000 000 population, for persistent cases
of depression and anxiety. CONCLUSIONS: This study showed important cost sav-
ings associated with AD use in persistent cases of depression and anxiety. Future
studies should focus on further exploring potential cost savings associated with
different classes of AD in the treatment of different clinical profiles of depression
and anxiety and this in the older adult population.
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OBJECTIVES: The objective of this study was to identify the demographic and clin-
ical characteristics of schizophrenia patients who experience high schizophrenia-
related directmedical costs.METHODS: Patientswith a diagnosis for schizophrenic
disorder (ICD-9-CM code 295) and other non-organic psychoses (ICD-9-CM code
298) were identified from the 2005-2008 Medical Expenditure Panel Survey (MEPS),
a national representative annual survey of non-institutionalized US residents.
Schizophrenia-related direct medical costs were calculated for the following utili-
zation categories: inpatient hospitalizations, prescriptionmedications, and outpa-
tient, office-based physician, emergency department, and home healthcare visits.
Based on the distribution of their total costs, patients were classified into high-cost
(expenditures$16,000) and low-cost (expenditures$16,000) groups. Logistic re-
gression was used to determine the likelihood of high-cost group membership
based on patient demographic and clinical characteristics. Generalized Linear
Models (GLM) regression was used to evaluate the relationships between the inde-
pendent variables and costs. RESULTS: There were 317 patients (weighted fre-
quency2.75 million) with schizophrenia-related costs. Based on the logistic re-
gression procedure, it was seen that older patients were less likely to be in the
high-cost group; for each one-year increase in age, patients were 6.4% less likely to
have high costs (odds ratio [OR]0.936). Patients with a spouse were 83.0% less
likely than those without a spouse to be in the high-cost group (OR0.170). The
GLM regression procedure showed that age, race, and region of residence were
significantly associated with costs. On controlling for other factors, with a one year
increase in age, costs decreased by $127 (p0.001), Caucasians spent $3,831
(p0.019) less than African Americans, and patients living in Southern US spent
$3,718 (p0.01) less than those living in the Northeast. CONCLUSIONS: Identifying
the high-risk population may help policy makers allocate resources more effi-
ciently andhealth care providersmanage patientsmore effectively through assign-
ment of high-risk patients to casemanagers and appropriatemonitoring and treat-
ment.
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OBJECTIVES: To estimate the schizophrenia-related direct medical costs using the
attributable and incremental cost approaches.METHODS: Patients with a diagno-
sis for schizophrenic disorder (ICD-9-CM code 295) and other non-organic psycho-
ses (ICD-9-CM code 298) were identified from the 2005-2008 Medical Expenditure
Panel Survey (MEPS), a nationally representative annual dataset of non-institution-
alized US residents. Schizophrenia-related direct medical costs were estimated for
inpatient hospitalizations, prescription medications, and outpatient, office-based
physician, emergency department, and homehealthcare visits, and overall. For the
attributable cost approach, schizophrenia-related costs were identified from each
of theMEPS event files. For the incremental cost approach, the differences between
the costs for patients with and without schizophrenia for each service type were
calculated to yield the schizophrenia-associated incremental costs. RESULTS:We
identified 348 patients with schizophrenia (weighted frequency3.03 million). The
mean schizophrenia-related direct medical cost per patient-year using the attrib-
utable cost approach was $5,538 (SE$570). With the incremental cost approach,
themean cost per patient-year was $12,369 (SE$1,205) for schizophrenia patients
and $3,198 (SE$47) for non-schizophrenia patients. Thus, the incremental cost
associated with schizophrenia was $9171 (SE1207) per patient-year. When demo-
graphic and clinical factors such as age, sex, race, marital status, insurance status,
socioeconomic status, region of residence, perceived health status, mental health
status, number of medical comorbidities, and number of mental health-related
comorbidities were controlled for using ordinary least squares regression, the
mean schizophrenia-related incremental direct medical cost per patient-year was
$5115 (SE$1240). CONCLUSIONS: This study highlights the high financial burden
of schizophrenia. Although the mean cost per patient-year estimated using the
incremental cost approach was higher than that obtained using the attributable
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